Peptide record

TPDB08054

HP(6-20) [E10K,S14K,Q17W,D19W] 50S ribosomal protein L1 HPA3NT3 Antibacterial Antifungal Antiviral Hemolysis Toxicity standard

15 amino acids

3D PDB MODEL

Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.

TPDB ID TPDB08054

Peptide_Name

HP(6-20) [E10K,S14K,Q17W,D19W] 50S ribosomal protein L1 HPA3NT3

Activity

Antibacterial Antifungal Antiviral Hemolysis Toxicity

Activity_category_statistics

Anti-infective peptides Toxicity and safety peptides

Database_Source

AntiBP3 dbAMP DRAMP Peptipedia AFP-GFuse Antifungipept CAFPdb HemoPI Hemolytic2 PD_Hemolysis DBAASP

Sequence_Type

standard

Has_Modification No

Description A 15-aa standard natural multi-activity (Antibacterial, Antifungal, Antiviral, and other sources) peptide sequence curated from AntiBP3, dbAMP, DRAMP, and other sources, with an available 3D structural model.

Sequence

FKRLKKLFKKIWNWK

FASTA

>TPDB08054|Antibacterial;Antifungal;Antiviral;Hemolysis;Toxicity|length=15
FKRLKKLFKKIWNWK

Formula C104H163N27O17

Absent Amino Acids ADCEQGHMPSTYV

Common Amino Acids K

Mass 2063.61

PI 11.90

Basic Residues 7

Acidic Residues 0

Hydrophobic Residues 7

Net Charge +7

Boman Index -0.22

Hydrophobicity -1.033

Aliphatic Index 78.00

Half Life

Mammalian: 1.1 hour Yeast: 3 min E.coli: 2 min

Extinction Coefficient Cystines 11000

Absorbance 280nm 533.05

Polar Residues 1

number

Amino Acid Distribution

A: 0 R: 1 N: 1 D: 0 C: 0 E: 0 Q: 0 G: 0 H: 0 I: 1 L: 2 K: 6 M: 0 F: 2 P: 0 S: 0 T: 0 W: 2 Y: 0 V: 0

Length

Formula

C104H163N27O17

Mass

2063.61

11.90

Net Charge

Boman Index

-0.22

Hydrophobicity

-1.033

Evidence 1 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antibacterial

Activity Measurement 4 µM

Target

Target Organism Escherichia coli

Source & Reference

Database Source dbAMP DRAMP

Other

Source Activity Label	Source Definition
Antibacterial	dbAMP classified as Antibacterial under the Anti-bacterial function class. DRAMP antibacterial activity supported by MIC records against bacterial target organisms.

Evidence Text

active against E. coli (MIC 4 uM) and S. aureus (MIC 32 uM) in MHB.

Evidence 2 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antibacterial

Activity Measurement 32 µM

Target

Target Organism Staphylococcus aureus

Source & Reference

Database Source dbAMP DRAMP

Other

Evidence Text

active against E. coli (MIC 4 uM) and S. aureus (MIC 32 uM) in MHB.

Evidence 3 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antifungal

Activity Measurement 4 µM

Target

Target Organism Escherichia coli

Source & Reference

Database Source dbAMP DRAMP CAFPdb Antifungipept

Other

Source Activity Label	Source Definition
Antifungal	dbAMP classified under the Anti-fungal function class. DRAMP antifungal activity supported by activity records against fungal target organisms.

Evidence Text

active against E. coli (MIC 4 uM) and S. aureus (MIC 32 uM) in MHB.

Evidence 4 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antifungal

Activity Measurement 32 µM

Target

Target Organism Staphylococcus aureus

Source & Reference

Database Source dbAMP DRAMP CAFPdb Antifungipept

Other

Evidence Text

active against E. coli (MIC 4 uM) and S. aureus (MIC 32 uM) in MHB.

Evidence 5 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antiviral

Activity Measurement 4 µM

Target

Target Organism Escherichia coli

Source & Reference

Database Source DRAMP

Other

Source Activity Label	Source Definition
Antiviral	DRAMP antiviral activity supported by activity records against viral targets.

Evidence Text

active against E. coli (MIC 4 uM) and S. aureus (MIC 32 uM) in MHB.

Evidence 6 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antiviral

Activity Measurement 32 µM

Target

Target Organism Staphylococcus aureus

Source & Reference

Database Source DRAMP

Other

Evidence Text

active against E. coli (MIC 4 uM) and S. aureus (MIC 32 uM) in MHB.

Evidence 7 Activity

Activity

Activity Endpoint 12% Hemolysis

Detail Source Activity Toxicity

Activity Measurement 100 µM

Toxicity Type Hemolytic Cytotoxic

Toxicity Raw

12% Hemolysis | 100 | µM | target cell: Human erythrocytes

Target

Target Cell Human erythrocytes

Source & Reference

Database Source NA

Source Database DBAASP

Reference

Amphipathic alpha-helical peptide, HP (2-20), and its analogues derived from Helicobacter pylori: pore formation mechanism in various lipid compositions. | Biochim Biophys Acta | 2008

Evidence 8 Activity

Activity

Activity Endpoint 71% Hemolysis

Detail Source Activity Toxicity

Activity Measurement 200 µM

Toxicity Type Hemolytic Cytotoxic

Toxicity Raw

71% Hemolysis | 200 | µM | target cell: Human erythrocytes

Target

Target Cell Human erythrocytes

Source & Reference

Database Source NA

Source Database DBAASP

Reference

Effect of Leucine and Lysine substitution on the antimicrobial activity and evaluation of the mechanism of the HPA3NT3 analog peptide. | J Pept Sci | 2009

Evidence 9 Activity

Activity

Detail Source Activity Toxicity

Toxicity Type Cytotoxic

Toxicity Raw

- | NA | target cell: Human keratinocytes HaCat

Target

Target Cell Human keratinocytes HaCat

Source & Reference

Database Source NA

Source Database DBAASP

Reference

Inhibitory and anti-inflammatory effects of the Helicobacter pylori-derived antimicrobial peptide HPA3NT3 against Propionibacterium acnes in the skin. | Br J Dermatol | 2014

Evidence 10 Activity

Activity

Activity Endpoint 68% Hemolysis

Detail Source Activity Toxicity

Activity Measurement 250 µM

Toxicity Type Hemolytic Cytotoxic

Toxicity Raw

68% Hemolysis | 250 | µM | target cell: Rat erythrocytes

Target

Target Cell Rat erythrocytes

Source & Reference

Database Source NA

Source Database DBAASP

Reference

Novel chimeric peptide with enhanced cell specificity and anti-inflammatory activity. | Biochem Biophys Res Commun | 2015

Evidence 11 Activity

Activity

Activity Endpoint 50% Cell death

Detail Source Activity Toxicity

Activity Measurement 49.5 µM

Toxicity Type Cytotoxic

Toxicity Raw

50% Cell death | 49.5 | µM | target cell: Human keratinocytes HaCat

Target

Target Cell Human keratinocytes HaCat

Source & Reference

Database Source NA

Source Database DBAASP

Reference

Novel chimeric peptide with enhanced cell specificity and anti-inflammatory activity. | Biochem Biophys Res Commun | 2015

Evidence 12 Activity

Activity

Activity Endpoint 10% Cytotoxicity

Detail Source Activity Toxicity

Activity Measurement 32 µg/mL

Toxicity Type Cytotoxic

Toxicity Raw

10% Cytotoxicity | 32 | µg/mL | target cell: Human keratinocytes HaCat

Target

Target Cell Human keratinocytes HaCat

Source & Reference

Database Source NA

Source Database DBAASP

Reference

Novel antimicrobial peptides against Cutibacterium acnes designed by deep learning | Research Square | 2023

Evidence 13 Activity

Activity

Activity Endpoint 10% Hemolysis

Detail Source Activity Toxicity

Activity Measurement 128 µg/mL

Toxicity Type Hemolytic Cytotoxic

Toxicity Raw

10% Hemolysis | 128 | µg/mL | target cell: Rabbit erythrocytes

Target

Target Cell Rabbit erythrocytes

Source & Reference

Database Source NA

Source Database DBAASP

Reference

Novel antimicrobial peptides against Cutibacterium acnes designed by deep learning | Research Square | 2023

Evidence 14 Activity

Activity

Activity Endpoint 0% Hemolysis

Detail Source Activity Toxicity

Activity Measurement 25 µM

Toxicity Type Hemolytic Cytotoxic

Toxicity Raw

0% Hemolysis | 25 | µM | target cell: Human erythrocytes

Target

Target Cell Human erythrocytes

Source & Reference

Database Source NA

Source Database DBAASP

Reference

ANTIBIOTIC PEPTIDE DERIVED FROM RIBOSOMAL PROTEIN L1 OF HELICOBACTER PYLORI AND USE THEREOF | PATENT US 8410046 B2 | 2013

Evidence 15 Activity

Activity

Activity Endpoint 7% Hemolysis

Detail Source Activity Toxicity

Activity Measurement 25 µM

Toxicity Type Hemolytic Cytotoxic

Toxicity Raw

7% Hemolysis | 25 | µM | target cell: Human erythrocytes

Target

Target Cell Human erythrocytes

Source & Reference

Database Source NA

Source Database DBAASP

Reference

ANTIBIOTIC PEPTIDE DERIVED FROM RIBOSOMAL PROTEIN L1 OF HELICOBACTER PYLORI AND USE THEREOF | PATENT US 8410046 B2 | 2013

Evidence 16 Activity

Activity

Activity Endpoint 11% Hemolysis

Detail Source Activity Toxicity

Activity Measurement 50 µM

Toxicity Type Hemolytic Cytotoxic

Toxicity Raw

11% Hemolysis | 50 | µM | target cell: Human erythrocytes

Target

Target Cell Human erythrocytes

Source & Reference

Database Source NA

Source Database DBAASP

Reference

ANTIBIOTIC PEPTIDE DERIVED FROM RIBOSOMAL PROTEIN L1 OF HELICOBACTER PYLORI AND USE THEREOF | PATENT US 8410046 B2 | 2013

Evidence 17 Activity

Activity

Activity Endpoint 37% Hemolysis

Detail Source Activity Toxicity

Activity Measurement 200 µM

Toxicity Type Hemolytic Cytotoxic

Toxicity Raw

37% Hemolysis | 200 | µM | target cell: Human erythrocytes

Target

Target Cell Human erythrocytes

Source & Reference

Database Source NA

Source Database DBAASP

Reference

ANTIBIOTIC PEPTIDE DERIVED FROM RIBOSOMAL PROTEIN L1 OF HELICOBACTER PYLORI AND USE THEREOF | PATENT US 8410046 B2 | 2013

Evidence 18 Activity

Activity

Activity Endpoint 69% Hemolysis

Detail Source Activity Toxicity

Activity Measurement 250 µM

Toxicity Type Hemolytic Cytotoxic

Toxicity Raw

69% Hemolysis | 250 | µM | target cell: Human erythrocytes

Target

Target Cell Human erythrocytes

Source & Reference

Database Source NA

Source Database DBAASP

Reference

Antimicrobial HPA3NT3 peptide analogs: placement of aromatic rings and positive charges are key determinants for cell selectivity and mechanism of action. | Biochim Biophys Acta | 2013

Evidence 19 Activity

Activity

Activity Endpoint 2.6% Hemolysis

Detail Source Activity Toxicity

Activity Measurement 15.625 µM

Toxicity Type Hemolytic Cytotoxic

Toxicity Raw

2.6% Hemolysis | 15.625 | µM | target cell: Sheep erythrocytes

Target

Target Cell Sheep erythrocytes

Source & Reference

Database Source NA

Source Database DBAASP

Reference

All d-Lysine Analogues of the Antimicrobial Peptide HPA3NT3-A2 Increased Serum Stability and without Drug Resistance | Int J Mol Sci | 2020

Evidence 20 Activity

Activity

Activity Endpoint 3.3% Hemolysis

Detail Source Activity Toxicity

Activity Measurement 31.25 µM

Toxicity Type Hemolytic Cytotoxic

Toxicity Raw

3.3% Hemolysis | 31.25 | µM | target cell: Sheep erythrocytes

Target

Target Cell Sheep erythrocytes

Source & Reference

Database Source NA

Source Database DBAASP

Reference

All d-Lysine Analogues of the Antimicrobial Peptide HPA3NT3-A2 Increased Serum Stability and without Drug Resistance | Int J Mol Sci | 2020

Evidence 21 Activity

Activity

Activity Endpoint 6.1% Hemolysis

Detail Source Activity Toxicity

Activity Measurement 62.5 µM

Toxicity Type Hemolytic Cytotoxic

Toxicity Raw

6.1% Hemolysis | 62.5 | µM | target cell: Sheep erythrocytes

Target

Target Cell Sheep erythrocytes

Source & Reference

Database Source NA

Source Database DBAASP

Reference

All d-Lysine Analogues of the Antimicrobial Peptide HPA3NT3-A2 Increased Serum Stability and without Drug Resistance | Int J Mol Sci | 2020

Evidence 22 Activity

Activity

Activity Endpoint 17.3% Hemolysis

Detail Source Activity Toxicity

Activity Measurement 125 µM

Toxicity Type Hemolytic Cytotoxic

Toxicity Raw

17.3% Hemolysis | 125 | µM | target cell: Sheep erythrocytes

Target

Target Cell Sheep erythrocytes

Source & Reference

Database Source NA

Source Database DBAASP

Reference

All d-Lysine Analogues of the Antimicrobial Peptide HPA3NT3-A2 Increased Serum Stability and without Drug Resistance | Int J Mol Sci | 2020

Evidence 23 Activity

Activity

Activity Endpoint 68.4% Hemolysis

Detail Source Activity Toxicity

Activity Measurement 250 µM

Toxicity Type Hemolytic Cytotoxic

Toxicity Raw

68.4% Hemolysis | 250 | µM | target cell: Sheep erythrocytes

Target

Target Cell Sheep erythrocytes

Source & Reference

Database Source NA

Source Database DBAASP

Reference

All d-Lysine Analogues of the Antimicrobial Peptide HPA3NT3-A2 Increased Serum Stability and without Drug Resistance | Int J Mol Sci | 2020

Evidence 24 Activity

Activity

Activity Endpoint 3% Cytotoxicity

Detail Source Activity Toxicity

Activity Measurement 15.625 µM

Toxicity Type Cytotoxic

Toxicity Raw

3% Cytotoxicity | 15.625 | µM | target cell: Human keratinocytes HaCat

Target

Target Cell Human keratinocytes HaCat

Source & Reference

Database Source NA

Source Database DBAASP

Reference

All d-Lysine Analogues of the Antimicrobial Peptide HPA3NT3-A2 Increased Serum Stability and without Drug Resistance | Int J Mol Sci | 2020

Evidence 25 Activity

Activity

Activity Endpoint 6% Cytotoxicity

Detail Source Activity Toxicity

Activity Measurement 31.25 µM

Toxicity Type Cytotoxic

Toxicity Raw

6% Cytotoxicity | 31.25 | µM | target cell: Human keratinocytes HaCat

Target

Target Cell Human keratinocytes HaCat

Source & Reference

Database Source NA

Source Database DBAASP

Reference

All d-Lysine Analogues of the Antimicrobial Peptide HPA3NT3-A2 Increased Serum Stability and without Drug Resistance | Int J Mol Sci | 2020

Evidence 26 Activity

Activity

Activity Endpoint 12% Cytotoxicity

Detail Source Activity Toxicity

Activity Measurement 62.5 µM

Toxicity Type Cytotoxic

Toxicity Raw

12% Cytotoxicity | 62.5 | µM | target cell: Human keratinocytes HaCat

Target

Target Cell Human keratinocytes HaCat

Source & Reference

Database Source NA

Source Database DBAASP

Reference

All d-Lysine Analogues of the Antimicrobial Peptide HPA3NT3-A2 Increased Serum Stability and without Drug Resistance | Int J Mol Sci | 2020

Evidence 27 Activity

Activity

Activity Endpoint 32% Cytotoxicity

Detail Source Activity Toxicity

Activity Measurement 125 µM

Toxicity Type Cytotoxic

Toxicity Raw

32% Cytotoxicity | 125 | µM | target cell: Human keratinocytes HaCat

Target

Target Cell Human keratinocytes HaCat

Source & Reference

Database Source NA

Source Database DBAASP

Reference

All d-Lysine Analogues of the Antimicrobial Peptide HPA3NT3-A2 Increased Serum Stability and without Drug Resistance | Int J Mol Sci | 2020

Evidence 28 Activity

Activity

Activity Endpoint 85.1% Cytotoxicity

Detail Source Activity Toxicity

Activity Measurement 250 µM

Toxicity Type Cytotoxic

Toxicity Raw

85.1% Cytotoxicity | 250 | µM | target cell: Human keratinocytes HaCat

Target

Target Cell Human keratinocytes HaCat

Source & Reference

Database Source NA

Source Database DBAASP

Reference

All d-Lysine Analogues of the Antimicrobial Peptide HPA3NT3-A2 Increased Serum Stability and without Drug Resistance | Int J Mol Sci | 2020

Evidence 29 Activity

Activity

Activity Endpoint % Hemolysis

Detail Source Activity Toxicity

Activity Measurement 32 %

Toxicity Type Hemolytic

Toxicity Raw

Hemolytic_activity: [Ref.19642077] 32% hemolysis at 50 µM , 46% hemolysis at 100 µM , 70% hemolysis at 200 µM against human red blood cells

Target

Target Cell erythrocytes

Source & Reference

Database Source NA

Source Database DRAMP

Reference

Biochim Biophys Acta. 2013 Feb 1828(2):443-454.##J Pept Sci. 2009 Sep 15(9):589-94. doi: 10.1002/psc.1155.

Evidence 30 Activity

Target

Target Organism Cutibacterium acnes

Source & Reference

Database Source DBAASP

Evidence 31 Hemolysis

Source & Reference

source HemoPI PD_Hemolysis

Database Source PD_Hemolysis